Provenge Nod Lifts Spirits And Stocks, But Also Sets High Bar For Success
This article was originally published in Pharmaceutical Approvals Monthly
Approval of Dendreon's Provenge is a major achievement and a shot in the arm for the growing field of therapeutic cancer vaccines, but it also serves as a reminder of the high bar for clinical and regulatory success in uncharted territory
You may also be interested in...
Having gotten over the hurdle of FDA approval with the market's first therapeutic cancer vaccine, Dendreon now faces the challenge of getting Provenge to the market. Already the company is also signaling that supply is unlikely to match demand in the near term
Analysts scramble to revise revenue forecasts upward after Dendreon releases high-end price and plans to go it alone in Europe
Cancer vaccine is approved for renal cell carcinoma in Russia, but still has not launched there due to prolonged reimbursement talks.